<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852967</url>
  </required_header>
  <id_info>
    <org_study_id>KD025-211</org_study_id>
    <nct_id>NCT02852967</nct_id>
  </id_info>
  <brief_title>A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety,&#xD;
      tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic&#xD;
      plaque psoriasis who are candidates for systemic therapy or phototherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2, two-period, dose-finding, placebo-controlled study is performed on adult male&#xD;
      and female subjects to evaluate the efficacy and safety of subjects with moderate to severe&#xD;
      chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.&#xD;
&#xD;
      Period 1: Double-blind, Placebo-controlled Treatment Period&#xD;
&#xD;
      Approximately 110 subjects are planned to be randomly assigned to each of 5 dose cohorts in a&#xD;
      1:1:1:1:1 manner. Each cohort is planned to have 22 subjects who meet eligibility criteria.&#xD;
      Subjects are treated with oral (PO) belumosudil tablets or placebo tablets as follows:&#xD;
&#xD;
        -  200 mg belumosudil once daily (QD) (Cohort 1) = one 200 mg belumosudil tablet and 1&#xD;
           matching placebo in the morning and 1 matching placebo in the evening&#xD;
&#xD;
        -  200 mg belumosudil twice daily (BID) (Cohort 2) = one 200 mg belumosudil tablet in the&#xD;
           morning and one matching placebo in the morning, and one 200 mg belumosudil tablet in&#xD;
           the evening&#xD;
&#xD;
        -  400 mg belumosudil QD (Cohort 3) = two 200 mg belumosudil tablets in the morning and one&#xD;
           matching placebo in the evening&#xD;
&#xD;
        -  600 mg/day belumosudil (Cohort 4) = two 200 mg belumosudil tablets in the morning and&#xD;
           one 200 mg belumosudil tablet in the evening&#xD;
&#xD;
        -  Matching placebo BID (Cohort 5) = 2 matching placebo tablets in the morning and 1&#xD;
           matching placebo tablet in the evening&#xD;
&#xD;
      Subjects in each of the 5 cohorts in Period 1 are treated with study medication for a period&#xD;
      of 16 weeks.&#xD;
&#xD;
      Note: Originally, a sample size of 36 subjects per cohort was planned to provide&#xD;
      approximately 90% probability ≥ 1 subject in the 5 cohorts would experience an adverse event&#xD;
      (AE) that had an underlying rate of ≥ 6% and approximately an 80% probability of ≥ 1 subject&#xD;
      in the cohort experiencing an AE that had an underlying rate of ≥ 4%. However, due to a newly&#xD;
      available plaque psoriasis treatment, the study is terminated early with 110 subjects.&#xD;
&#xD;
      Period 2: Open-label Treatment Period (with Belumosudil)&#xD;
&#xD;
      All subjects treated for 16 weeks, regardless of treatment with belumosudil (Cohorts 1&#xD;
      through 4) or placebo (Cohort 5) are given the option to receive 400 mg belumosudil QD for an&#xD;
      additional 32 weeks (Week 16 through Week 48).&#xD;
&#xD;
      Follow-up Period&#xD;
&#xD;
      All subjects have a safety evaluation 30 days after the last dose of study drug.&#xD;
&#xD;
      Efficacy is assessed by the following scores at scheduled time points throughout the study:&#xD;
&#xD;
        -  Psoriasis Area and Severity Index (PASI): Measure of psoriasis disease severity using&#xD;
           average redness, thickness, and scaliness of lesions (each lesion graded 0 to 4),&#xD;
           combined into single score ranging on a scale from 0 (no disease) to 72 (maximum&#xD;
           disease)&#xD;
&#xD;
        -  Physician's Global Assessment (PGA): Physician's assessment of a subject's psoriasis,&#xD;
           relative to baseline, ranging on a scale from 1 (100% clearing of psoriasis) to 6 (poor&#xD;
           to no clearing)&#xD;
&#xD;
        -  Dermatology Life Quality Index (DLQI): Skin disease-specific instrument for assessing&#xD;
           impact of disease on subject's quality of life ranging on a scale from 0 (no effect on&#xD;
           subject's life) to 30 (extremely large effect on subject's life)&#xD;
&#xD;
      Safety is assessed by;&#xD;
&#xD;
        -  AEs and serious AE (SAEs)&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Vital sign measurements&#xD;
&#xD;
        -  Clinical laboratory evaluations&#xD;
&#xD;
        -  Electrocardiogram&#xD;
&#xD;
        -  Reasons for discontinuation due to toxicity analyses&#xD;
&#xD;
      The maximum duration for subjects who complete Period 1 (Double-blind, Placebo-controlled) is&#xD;
      24 weeks (up to 4-week Screening, 16-week Period 1 treatment, and 4-week Follow-up). The&#xD;
      maximum duration for subjects who complete Period 2 (Open-label) is 56 weeks (up to 4-week&#xD;
      Screening, 16-week Double-blind Treatment Period, 32-week Open-label Treatment Period, and&#xD;
      4-week Follow-up).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed</measure>
    <time_frame>16 weeks</time_frame>
    <description>The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward [LOCF]) and those who did complete 16 weeks of treatment (observed).&#xD;
[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed</measure>
    <time_frame>48 weeks</time_frame>
    <description>The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward [LOCF]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results.&#xD;
[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed</measure>
    <time_frame>48 weeks</time_frame>
    <description>The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward [LOCF]) or for only those subjects who completed 16 and 48 weeks (observed), respectively.&#xD;
[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of subjects who had a &quot;Clear&quot; or &quot;Almost Clear&quot; assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward [LOCF]) [The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF</measure>
    <time_frame>16 weeks</time_frame>
    <description>The percentage (%) of subjects who had a &quot;Clear&quot; or &quot;Almost Clear&quot; assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward [LOCF]).&#xD;
[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment).&#xD;
[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change &lt; 0% is improvement; &gt; 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment).&#xD;
[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.]</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Belumosudil 200 mg QD + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belumosudil 200 mg BID (Twice Daily) + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belumosudil 400 mg QD + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belumosudil 600 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belumosudil</intervention_name>
    <arm_group_label>Belumosudil 200 mg BID (Twice Daily) + Placebo</arm_group_label>
    <arm_group_label>Belumosudil 200 mg QD + Placebo</arm_group_label>
    <arm_group_label>Belumosudil 400 mg QD + Placebo</arm_group_label>
    <arm_group_label>Belumosudil 600 mg/day</arm_group_label>
    <other_name>Rezurock (brand name)</other_name>
    <other_name>KD025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching belumosudil</description>
    <arm_group_label>Belumosudil 200 mg BID (Twice Daily) + Placebo</arm_group_label>
    <arm_group_label>Belumosudil 200 mg QD + Placebo</arm_group_label>
    <arm_group_label>Belumosudil 400 mg QD + Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects between the ages of 18 and 65 years&#xD;
&#xD;
          -  Able to provide written Informed Consent Form prior to the performance of any&#xD;
             study-specific procedures&#xD;
&#xD;
          -  Diagnosis of moderate to severe chronic plaque psoriasis and a candidate for systemic&#xD;
             therapy or phototherapy&#xD;
&#xD;
          -  PASI of ≥ 12 at screening and prior to the first dose of study drug, confirmed at Week&#xD;
             1 Day 1 (Baseline)&#xD;
&#xD;
          -  ≥ 10% PASI body surface area involvement at screening and prior to the first dose of&#xD;
             study drug, confirmed at Baseline&#xD;
&#xD;
          -  Willing to avoid tanning devices&#xD;
&#xD;
          -  Adequate bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1500/mm^3&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm^3&#xD;
&#xD;
          -  Adequate safety laboratory values:&#xD;
&#xD;
               -  Serum total bilirubin within normal limits (WNL)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alalnine aminotransferase (ALT) &lt; 2 × upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 × ULN&#xD;
&#xD;
          -  Female subjects of childbearing potential with a negative pregnancy test at screening.&#xD;
             Females of childbearing potential were defined as sexually mature women without prior&#xD;
             hysterectomy or who had any evidence of menses in the past 12 months. However, women&#xD;
             who had been amenorrheic for 12 or more months were still considered to be of&#xD;
             childbearing potential if the amenorrhea was possibly due to prior chemotherapy,&#xD;
             antiestrogens, or ovarian suppression&#xD;
&#xD;
               -  Women of childbearing potential (i.e., menstruating women) had to have a negative&#xD;
                  urine pregnancy test (positive urine tests were to be confirmed by serum test)&#xD;
                  documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
               -  Sexually active women of childbearing potential enrolled in the study had to&#xD;
                  agree to use 2 forms of accepted methods of contraception during the course of&#xD;
                  the study and for 3 months after their last dose of study drug. Effective birth&#xD;
                  control included: (a) intrauterine device plus 1 barrier method; (b) on stable&#xD;
                  doses of hormonal contraception for at least 3 months (e.g., oral, injectable,&#xD;
                  implant, transdermal) plus one barrier method; and (c) 2 barrier methods.&#xD;
                  Effective barrier methods were male or female condoms, diaphragms, and&#xD;
                  spermicides (creams or gels that contained a chemical to kill sperm); or (d) a&#xD;
                  vasectomized partner&#xD;
&#xD;
          -  For male patients who were sexually active and who were partners of premenopausal&#xD;
             women: agreed to use 2 forms of contraception as defined above during the treatment&#xD;
             period and for at least 3 months after the last dose of study drug&#xD;
&#xD;
          -  Willing to complete all study measurements and assessments in compliance with the&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-plaque or drug-induced (antimalarials, lithium) psoriasis (If subject was taking&#xD;
             angiotensin II receptor blockers or beta blockers doses must have been stable for 6&#xD;
             months prior to study entry)&#xD;
&#xD;
          -  Used systemic corticosteroids within 12 weeks prior to study entry&#xD;
&#xD;
          -  Used topical corticosteroids except to the face, groin, or scalp&#xD;
&#xD;
          -  Used methotrexate, retinoids (such as acitretin), or calcineurin inhibitors (such as&#xD;
             cyclosporine) within 4 weeks prior to study entry&#xD;
&#xD;
          -  Phototherapy within 4 weeks prior to study entry&#xD;
&#xD;
          -  Biologic therapies, including antibodies to IL-17; anti-tumor necrosis factor-alpha;&#xD;
             and anti-IL-12 &amp; IL-23 within 3 months prior to study entry&#xD;
&#xD;
          -  Current use of an inhibitor or inducer of CYP3A4&#xD;
&#xD;
          -  Active viral, fungal, or bacterial skin infection (other than nail fungal infection).&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  History of gastrointestinal (GI) surgery including any bariatric surgery, or any GI&#xD;
             condition that might interfere with drug absorption&#xD;
&#xD;
          -  Participating in another study with an investigational drug or within 28 days or 5&#xD;
             half-lives of the investigational drug (whichever was longer) of study entry&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions that would make&#xD;
             the subject, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  Regular and/or excessive use of alcohol within 2 years prior to study entry defined as&#xD;
             alcohol intake &gt; 14 drinks per week in a man or &gt; 7 drinks per week in a woman.&#xD;
             Approximately 10 g of alcohol equaled one &quot;drink&quot; unit. One unit equaled 1 ounce of&#xD;
             distilled spirits, one 12-ounce beer, or one 4-ounce glass of wine&#xD;
&#xD;
          -  QT interval data corrected using Fridericia's formula (QTcF) &gt; 450 msec (average of 3&#xD;
             readings) during screening&#xD;
&#xD;
          -  Exposure to belumosudil or known allergy/sensitivity to belumosudil within the last 6&#xD;
             months prior to study entry or any other ROCK-2 inhibitor&#xD;
&#xD;
          -  History or presence of any of the following:&#xD;
&#xD;
               -  ALT or AST &gt; 2.0 × ULN at screening&#xD;
&#xD;
               -  Renal disease and/or serum creatinine &gt; 1.5 × ULN at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alliance Dermatology and Mohs Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine - Dermatology Clinical Research Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Dermatology Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Boston Clinical Partners</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <results_first_submitted>August 13, 2021</results_first_submitted>
  <results_first_submitted_qc>August 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <disposition_first_submitted>April 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 20, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 24, 2020</disposition_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin Diseases</keyword>
  <keyword>Auto-Immune Diseases</keyword>
  <keyword>Plaque</keyword>
  <keyword>Dermatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02852967/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02852967/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Belumosudil 200 mg QD + Placebo</title>
          <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="P2">
          <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
          <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="P3">
          <title>Belumosudil 400 mg QD + Placebo</title>
          <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="P4">
          <title>Belumosudil 600 mg/Day</title>
          <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Period 1: Double-blind</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Period 2: Open-label</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elevated Liver Enzymes</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dispensing Drug Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belumosudil 200 mg QD + Placebo</title>
          <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="B2">
          <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
          <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="B3">
          <title>Belumosudil 400 mg QD + Placebo</title>
          <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="B4">
          <title>Belumosudil 600 mg/Day</title>
          <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="18"/>
            <count group_id="B6" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="8.9"/>
                    <measurement group_id="B2" value="46.2" spread="9.6"/>
                    <measurement group_id="B3" value="43.0" spread="11.4"/>
                    <measurement group_id="B4" value="43.5" spread="11.5"/>
                    <measurement group_id="B5" value="45.7" spread="14.2"/>
                    <measurement group_id="B6" value="45.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Mean)</title>
          <description>Body mass index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="9.9"/>
                    <measurement group_id="B2" value="30.7" spread="7.0"/>
                    <measurement group_id="B3" value="29.9" spread="7.4"/>
                    <measurement group_id="B4" value="33.1" spread="10.7"/>
                    <measurement group_id="B5" value="32" spread="6.7"/>
                    <measurement group_id="B6" value="32.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed</title>
        <description>The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward [LOCF]) and those who did complete 16 weeks of treatment (observed).&#xD;
[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>16 weeks</time_frame>
        <population>PASI 75 determined by Last Observation Carried Forward (LOCF) and Observed at the end of Double-blind Period: 16 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O6">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed</title>
          <description>The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward [LOCF]) and those who did complete 16 weeks of treatment (observed).&#xD;
[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>PASI 75 determined by Last Observation Carried Forward (LOCF) and Observed at the end of Double-blind Period: 16 weeks</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LOCF (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="1.1" upper_limit="28.0"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O4" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                    <measurement group_id="O5" value="16.7" lower_limit="3.6" upper_limit="41.4"/>
                    <measurement group_id="O6" value="10.9" lower_limit="5.3" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Observed (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                    <measurement group_id="O2" value="13.3" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O3" value="23.5" lower_limit="6.8" upper_limit="49.9"/>
                    <measurement group_id="O4" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O5" value="30.0" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O6" value="14.5" lower_limit="6.9" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>LOCF at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 200 mg QD + placebo (n = 23) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 18) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6384</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LOCF at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 200 mg BID + placebo (n = 22) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 18) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6419</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LOCF at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 400 mg QD + placebo (n = 21) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 18) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LOCF at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 600 mg (n = 26) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 18) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3859</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>LOCF at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of all subjects treated with belumosudil (n = 92) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 18) who achieved PASI 75</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4435</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Observed at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 200 mg QD + placebo (n = 14) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 10) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2721</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Observed at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 200 mg BID+ Placebo (n = 15) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 10) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3577</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Observed at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 500 mg QD + Placebo (n = 17) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 10) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Observed at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of subjects treated with belumosudil 600 mg/day (n = 16) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 10) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3402</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Observed at 16 weeks (Double-blind Treatment Period): Fisher's Exact Method analysis of the percentage of all subjects treated with belumosudil 200 mg QD + Placebo (n = 62) who achieved PASI 75 compared to the percentage of subjects treated with placebo (n = 10) who achieved PASI 75.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3542</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed</title>
        <description>The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward [LOCF]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results.&#xD;
[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>48 weeks</time_frame>
        <population>Not all subjects had PASI performed</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O6">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed</title>
          <description>The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward [LOCF]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results.&#xD;
[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Not all subjects had PASI performed</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.93" spread="8.31"/>
                    <measurement group_id="O2" value="20.60" spread="8.27"/>
                    <measurement group_id="O3" value="18.82" spread="6.08"/>
                    <measurement group_id="O4" value="19.80" spread="9.03"/>
                    <measurement group_id="O5" value="20.72" spread="8.08"/>
                    <measurement group_id="O6" value="19.55" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16--LOCF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.69" spread="8.59"/>
                    <measurement group_id="O2" value="-4.49" spread="7.44"/>
                    <measurement group_id="O3" value="-5.0" spread="8.31"/>
                    <measurement group_id="O4" value="-4.63" spread="8.04"/>
                    <measurement group_id="O5" value="-5.68" spread="12.31"/>
                    <measurement group_id="O6" value="-4.96" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16--Observed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" spread="8.62"/>
                    <measurement group_id="O2" value="-6.29" spread="6.45"/>
                    <measurement group_id="O3" value="-4.96" spread="8.72"/>
                    <measurement group_id="O4" value="-3.81" spread="5.37"/>
                    <measurement group_id="O5" value="-8.44" spread="15.36"/>
                    <measurement group_id="O6" value="-4.71" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48--LOCF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.85" spread="10.53"/>
                    <measurement group_id="O2" value="-6.38" spread="5.16"/>
                    <measurement group_id="O3" value="-9.01" spread="7.63"/>
                    <measurement group_id="O4" value="-0.83" spread="7.73"/>
                    <measurement group_id="O5" value="-9.56" spread="18.98"/>
                    <measurement group_id="O6" value="-5.11" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48--Observed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.93" spread="11.26"/>
                    <measurement group_id="O2" value="-5.30" spread="5.88"/>
                    <measurement group_id="O3" value="-12.99" spread="6.71"/>
                    <measurement group_id="O4" value="-4.27" spread="2.16"/>
                    <measurement group_id="O5" value="9.45" spread="21.00"/>
                    <measurement group_id="O6" value="-7.98" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed</title>
        <description>The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward [LOCF]) or for only those subjects who completed 16 and 48 weeks (observed), respectively.&#xD;
[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>48 weeks</time_frame>
        <population>Not all subjects had PASI performed</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O6">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed</title>
          <description>The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward [LOCF]) or for only those subjects who completed 16 and 48 weeks (observed), respectively.&#xD;
[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Not all subjects had PASI performed</population>
          <units>Percentage Change in PASI Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change (%) at Week 16--LOCF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.17" spread="37.60"/>
                    <measurement group_id="O2" value="-19.61" spread="35.60"/>
                    <measurement group_id="O3" value="-24.31" spread="42.74"/>
                    <measurement group_id="O4" value="-20.07" spread="31.20"/>
                    <measurement group_id="O5" value="-18.23" spread="43.93"/>
                    <measurement group_id="O6" value="-22.78" spread="36.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (%) at Week 16--Observed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.21" spread="36.90"/>
                    <measurement group_id="O2" value="-29.70" spread="30.72"/>
                    <measurement group_id="O3" value="-24.17" spread="44.61"/>
                    <measurement group_id="O4" value="-20.22" spread="30.16"/>
                    <measurement group_id="O5" value="-25.09" spread="54.31"/>
                    <measurement group_id="O6" value="-22.46" spread="35.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (%) at Week 48--LOCF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.82" spread="40.33"/>
                    <measurement group_id="O2" value="-30.75" spread="24.51"/>
                    <measurement group_id="O3" value="-46.97" spread="39.90"/>
                    <measurement group_id="O4" value="-9.31" spread="41.28"/>
                    <measurement group_id="O5" value="-19.89" spread="90.61"/>
                    <measurement group_id="O6" value="-25.54" spread="39.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (%) at Week 48--Observed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.81" spread="38.75"/>
                    <measurement group_id="O2" value="-30.02" spread="34.39"/>
                    <measurement group_id="O3" value="-63.04" spread="29.04"/>
                    <measurement group_id="O4" value="-33.16" spread="15.48"/>
                    <measurement group_id="O5" value="84.98" spread="166.19"/>
                    <measurement group_id="O6" value="-38.33" spread="36.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF</title>
        <description>The number of subjects who had a &quot;Clear&quot; or &quot;Almost Clear&quot; assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward [LOCF]) [The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.]</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O6">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF</title>
          <description>The number of subjects who had a &quot;Clear&quot; or &quot;Almost Clear&quot; assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward [LOCF]) [The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.]</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF</title>
        <description>The percentage (%) of subjects who had a &quot;Clear&quot; or &quot;Almost Clear&quot; assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward [LOCF]).&#xD;
[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.]</description>
        <time_frame>16 weeks</time_frame>
        <population>Not all subjects had a response to treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF</title>
          <description>The percentage (%) of subjects who had a &quot;Clear&quot; or &quot;Almost Clear&quot; assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward [LOCF]).&#xD;
[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.]</description>
          <population>Not all subjects had a response to treatment</population>
          <units>Percentage (%) of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" lower_limit="-23.5" upper_limit="10.0"/>
                    <measurement group_id="O2" value="-11.1" lower_limit="-25.6" upper_limit="3.4"/>
                    <measurement group_id="O3" value="-1.6" lower_limit="-20.8" upper_limit="17.6"/>
                    <measurement group_id="O4" value="-7.3" lower_limit="-23.6" upper_limit="9.0"/>
                    <measurement group_id="O5" value="-6.8" lower_limit="-21.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects treated with belumosudil compared to placebo who had a PGA rating of clear or almost clear</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5728</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects treated with belumosudil compared to placebo who had a PGA rating of clear or almost clear</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1962</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Percentage of subjects treated with belumosudil compared to placebo who had a PGA rating of clear or almost clear</non_inferiority_desc>
            <p_value>&gt; 0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects treated with belumosudil compared to placebo who had a PGA rating of clear or almost clear</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5583</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects treated with belumosudil compared to placebo who had a PGA rating of clear or almost clear</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2538</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48</title>
        <description>Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment).&#xD;
[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change &lt; 0% is improvement; &gt; 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.]</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>Not all subjects could be evaluated at all visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O6">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48</title>
          <description>Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment).&#xD;
[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change &lt; 0% is improvement; &gt; 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.]</description>
          <population>Not all subjects could be evaluated at all visits.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="6.3"/>
                    <measurement group_id="O2" value="16.5" spread="9.4"/>
                    <measurement group_id="O3" value="12.2" spread="6.5"/>
                    <measurement group_id="O4" value="11.0" spread="7.1"/>
                    <measurement group_id="O5" value="10.3" spread="6.4"/>
                    <measurement group_id="O6" value="12.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="5.6"/>
                    <measurement group_id="O2" value="-3.4" spread="4.0"/>
                    <measurement group_id="O3" value="-2.5" spread="6.0"/>
                    <measurement group_id="O4" value="-2.3" spread="7.0"/>
                    <measurement group_id="O5" value="-4.0" spread="6.7"/>
                    <measurement group_id="O6" value="-2.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.1"/>
                    <measurement group_id="O2" value="-1.0" spread="8.6"/>
                    <measurement group_id="O3" value="-5.2" spread="6.9"/>
                    <measurement group_id="O4" value="-3.7" spread="3.2"/>
                    <measurement group_id="O5" value="-3.0" spread="2.8"/>
                    <measurement group_id="O6" value="-4.7" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48</title>
        <description>Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment).&#xD;
[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.]</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>Not all subjects could be evaluated at all visits. Mean decrease in mean DLQI score is favorable; mean increase is not favorable</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg QD + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
            <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O3">
            <title>Belumosudil 400 mg QD + Placebo</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O4">
            <title>Belumosudil 600 mg/Day</title>
            <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
          </group>
          <group group_id="O6">
            <title>All Belumosudil</title>
            <description>All subjects in the Belumosudil 200 mg QD, 200 mg BID, 400 mg QD, and 600 mg/day cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48</title>
          <description>Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment).&#xD;
[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.]</description>
          <population>Not all subjects could be evaluated at all visits. Mean decrease in mean DLQI score is favorable; mean increase is not favorable</population>
          <units>Percentage change of DLQI score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.73" spread="60.75"/>
                    <measurement group_id="O2" value="-14.8" spread="28.78"/>
                    <measurement group_id="O3" value="-22.22" spread="48.60"/>
                    <measurement group_id="O4" value="-6.4" spread="79.95"/>
                    <measurement group_id="O5" value="-40.30" spread="47.83"/>
                    <measurement group_id="O6" value="-12.55" spread="56.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.41" spread="86.97"/>
                    <measurement group_id="O2" value="3.54" spread="54.32"/>
                    <measurement group_id="O3" value="-45.60" spread="45.84"/>
                    <measurement group_id="O4" value="-53.73" spread="45.24"/>
                    <measurement group_id="O5" value="-54.17" spread="41.25"/>
                    <measurement group_id="O6" value="-33.11" spread="65.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 52 weeks: up to 48 weeks of treatment and 30-day follow-up</time_frame>
      <desc>Subjects were followed for adverse events from the signing of the consent form to the 30-day follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Belumosudil 200 mg QD + Placebo</title>
          <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="E2">
          <title>Belumosudil 200 mg BID (Twice Daily) + Placebo</title>
          <description>One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="E3">
          <title>Belumosudil 400 mg QD + Placebo</title>
          <description>Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Belumosudil: Belumosudil tablets&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="E4">
          <title>Belumosudil 600 mg/Day</title>
          <description>Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening&#xD;
Belumosudil: Belumosudil tablets</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening&#xD;
Placebo: Placebo tablets matching belumosudil</description>
        </group>
        <group group_id="E6">
          <title>All Belumosudil</title>
          <description>All subjects from all cohorts who received belumosudil</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Natural death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease (COPD)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Ligament pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Meniscus injry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransaminase (ALT) increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olivier Schueller, Senior Vice President, CMC &amp; Clinical Pharmacology</name_or_title>
      <organization>Kadmon Corporation, LLC</organization>
      <phone>724-778-6170</phone>
      <email>olivier.schueller@kadmon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

